Taken together, selective targeting of the ATR/Chk1 pathway offers a promising therapeutic approach for cancer treatment in a broad range of tumours in both monotherapy and for the purpose of selectively sensitizing cancer cells to current genotoxic treatment. Here, CHEK1 is linked to cancer.